The Tough Tech problem we are solving
Patient-specific cells provide the safest, most effective cures for many chronic degenerative diseases. However, current autologous (patient-specific) processes are not scalable due to extensive manual handling, high variability, and expensive facility overhead. The traditional, artisanal procedure to generate iPSCs (induced pluripotent stem cells) relies on human decision making and manual picking procedures carried out by highly skilled operators. This process is highly prone to operator bias and is not scalable, which limits the ability to produce personalized iPSC-derived therapies for all patients in need.
About our solution
Cellino is building a multidisciplinary platform to scale production of autologous iPSC-derived therapies. The platform utilizes image-guided machine learning algorithms to characterize cells and colonies, a laser processing technology to remove unwanted cells and purify cell populations, and robotics to automate liquid handling processes. Cellino aims to industrialize the iPSC generation process and enable scalable and cost-effective manufacturing of autologous iPSC-derived therapies for patients.